...Correlation between pre-treatment PD-L1 expression level and FFS`Correlation between pre-treatment PD-L1 expression level and OS`Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and PFS`Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and OS`Evaluate failure-free survival in the subgroup of age at diagnosis (year)`Evaluate failure-free survival in the subgroup of gender (male and female)`Evaluate failure-free survival in the subgroup of plasma Epstein-Barr virus DNA level`Evaluate failure-free survival in the subgroup of clinical stage`Evaluate the regression of tumor and parotid glands during radiotherapy...

...Overall Survival (OS)`Locoregional Relapse-Free Survival (LRRFS)`Distant Metastasis-Free Survival (DMFS)`Objective Response Rate （ORR）`Incidence rate of adverse events (AEs)`Correlation between the plasma EBV DNA level and PFS`Correlation between pre-treatment PD-L1 expression level and PFS`Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and PFS`Change of QoL (quality of life)`Number of subjects with major pathologic response (MPR)...

A consistent effect on overall survival, favoring toripalimab, was found in subgroups with high and low PD-L1 (programmed death–ligand 1) expression….The addition of toripalimab to chemotherapy as first-line treatment for RM-NPC provided statistically significant and clinically meaningful progression-free survival and overall survival benefits compared with chemotherapy alone, with a manageable safety profile. These findings support the use of toripalimab plus gemcitabine-cisplatin as the new standard of care for this patient population.